Characteristics of Hospitalized Patients With Community-acquired Pneumonia

Sponsor
Qianfoshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06065618
Collaborator
(none)
200
1
12
16.6

Study Details

Study Description

Brief Summary

At present, the epidemiological characteristics and the distribution of pathogens of community-acquired pneumonia in Shandong Province are not clear. In order to understand the characteristics of community-acquired pneumonia, the distribution of pathogens and the risk factors of complications in Shandong Province, it is necessary to carry out investigation and study, which will provide the basis and support for the future prospective cohort study of pulmonary infection.

Condition or Disease Intervention/Treatment Phase
  • Other: Without intervention

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
A Retrospective Study on Disease Characteristics of Hospitalized Patients With Community-acquired Pneumonia
Actual Study Start Date :
Sep 22, 2023
Anticipated Primary Completion Date :
Sep 22, 2024
Anticipated Study Completion Date :
Sep 22, 2024

Outcome Measures

Primary Outcome Measures

  1. The prevalence of CAP [Up to 12 months]

    The prevalence of CAP

Secondary Outcome Measures

  1. Severity Assessment: Curb-65 [Up to 12 months]

    Curb-65 is mainly used to evaluate the severity of pneumonia. The clinical indexes of curb-65 include: 1. Disturbance of consciousness, 2. Blood urea nitrogen > 7 mmol/L, 3. Respiratory frequency ≥30 times/min, 3. The severity of pneumonia 4. Systolic blood pressure < 90 mmhg or diastolic blood pressure ≤60 mmhg. 5. Age ≥65 years. If curb-65 score is 0-1, it is recommended that the patient be treated outside the hospital. Curb-65 has a score of 2 and is recommended for short-term hospitalization. If curb-65 score ≥3 indicates severe pneumonia, hospitalization or ICU treatment is recommended. With the increase of curb-65 score, the mortality of the patients will increase accordingly.

  2. Sputum culture [Up to 12 months]

    According to the need for aerobic bacteria culture, anaerobic bacteria culture, Mycobacterium tuberculosis culture, or fungal culture, for the etiological diagnosis of respiratory infection.

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Age > 14 years.

  • In the community.

  • Chest X-ray showed patchy, patchy infiltrative shadows or interstitial changes with or without pleural effusion (in or out of hospital) .

  • Pneumonia-related clinical manifestations: 1) recent cough, expectoration or respiratory disease symptoms aggravated, and the emergence of purulent sputum, with or without chest pain. 2) fever: armpit temperature ≥37.3℃ or hypothermia: armpit temperature <36℃. 3) signs of pulmonary consolidation and/or Wet Rales. 4) white blood cell > 10 × 109/L or < 4 × 109/L with or without left shift of nucleus. Comply with 1,2,3 above plus any one of 4 above.

Exclusion Criteria:
  • The patients were initially diagnosed with pulmonary neoplasms, tuberculosis, non-infectious interstitial disease, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophil granulocyte infiltration and pulmonary vasculitis.

  • Human Immunodeficiency Virus.

  • The patient was readmitted within 72 hours of discharge and was classified as a single hospitalization.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China Jinan Shandong China 250014

Sponsors and Collaborators

  • Qianfoshan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Qian Qi, Principal Investigator, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT06065618
Other Study ID Numbers:
  • YXLL-KY-2022(080)
First Posted:
Oct 4, 2023
Last Update Posted:
Oct 10, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 10, 2023